HERON Obtained Medical Device License of AB-BNCT system in Taiwan

HERON today officially obtained the medical device license of AB-BNCT equipment, which marks an important milestone in the field of cancer treatment in Taiwan. In the future, we will work closely with major medical centers to develop the clinical application of BNCT and bring new tools for cancer treatment to patients. Since the technology transfer from Tsinghua University and Industrial Technology Research Institute (ITRI) in 2017, HERON has focused on the development of AB-BNCT technology. The successful symbolizes Taiwan's ability to develop cancer treatment systems in-house, instead of relying on foreign vendors. The technological breakthrough not only proves the excellent technical ability of Taiwan, but also the neutron efficiency of its patented technology is the top in the world. Compared with similar systems from international manufacturers, it has lower activation and effectively reduces radiation exposure. HERON is ready to be based in Taiwan and step into the world.
 HERON will launch clinical trials this year. The boron-containing drug BPA developed in cooperation with CDMO company to target recurrent head and neck cancers and will collaborate with medical centers in the north, central, and south of Taiwan to conduct clinical trials. We hope the trials will be completed and the drug license will be obtained in 2026. At the same time, research-based trials will also be conducted, including meningioma, brain cancer, breast cancer and lung cancer. The clinical medicine center of HERON has already begun planning for the expansion of the indications in the future.
 Cancer has been the top cause of death in Taiwan. Accurate diagnosis and personalized treatment are the top medical issues. In tandem with the government's policy of developing the precision medicine, HERON has developed a screening technology (F18-BPA) to make the diagnosis more accurate. This technology (F18-BPA) not only provides an indicator to predict the efficacy of treatment, but also provides a scientific basis for commercial insurance and NHI benefits in the future.

We will continue to improve AB-BNCT technology to bring revolutionary breakthrough to cancer treatment in Taiwan, benefit more cancer patients and go international which are the strategic goal of HERON.

HERON Obtains Taiwan's First Medical Device License of AB-BNCT System.